# AstraZeneca: Phase 3 study closed enrollment, 768 enrolled (Metastatic Non-small Cell Lung Cancer)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT ID | NCT06417814 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Metastatic Non-small Cell Lung Cancer |
| Intervention types | drug |
| Target enrollment | 768 |
| Site countries | United States, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Hong Kong, India, Israel |
| Posted | 2024-05-16 |
| Planned start | 2024-10-04 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-15 |
| Last update posted | 2026-10-15 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 768 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06417814). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.